Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individualised N-terminal Pro-B-type Natriuretic Peptide Thresholds for the Diagnosis of Heart Failure: A Proof-of-Concept Study.

Cureus·2026
Same author

Circulating Endotrophin Predicts Myocardial Fibrosis Burden and Is Sensitive to Antifibrotic Therapy.

JACC. Advances·2026
Same author

Characterising the heterogeneity of heart failure with preserved ejection fraction: moving beyond subgroups and distinguishing disease from risk.

European journal of heart failure·2026
Same author

Overcoming Hyperkalaemia as a Barrier to Achieving Optimal RAASi Therapy and Cardiorenal Protection in Individuals with Cardiorenal Disease: A Podcast Discussion.

Advances in therapy·2026
Same author

Expert Perspectives on Managing Iron Deficiency in People with CKD and/or HF.

Journal of clinical medicine·2026
Same author

Physiological Normothermic Machine Perfusion Enhances Kidney Preservation Versus the Established UK Normothermic Machine Perfusion Assessment Protocol.

Kidney360·2025

Related Experiment Video

Updated: Jul 4, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Pleiotropic effects and cholesterol-lowering therapy.

Steven M Shaw1, James E Fildes, Nizar Yonan

  • 1North West Regional Cardiac and Transplant Unit, University of South Manchester NHS Foundation Trust, Manchester, UK. doctorshaw@doctors.org.uk

Cardiology
|June 26, 2008
PubMed
Summary
This summary is machine-generated.

Statins offer cardiovascular benefits beyond lowering LDL cholesterol, potentially through pleiotropic effects on inflammation and thrombosis. However, the independent contribution of these effects requires further investigation and critical analysis.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Experiment Videos

Last Updated: Jul 4, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Statins (HMG-CoA reductase inhibitors) are crucial in managing atherosclerotic vascular disease.
  • Clinical observations suggest benefits beyond LDL cholesterol reduction, appearing rapidly after treatment initiation.
  • Experimental data indicate statins may impact inflammation, thrombosis, and endothelial function via the mevalonate pathway.

Purpose of the Study:

  • To critically analyze the evidence for pleiotropic effects of statins.
  • To evaluate the contribution of non-lipid-lowering mechanisms to cardiovascular event reduction.
  • To highlight outstanding questions regarding statin's independent benefits.

Main Methods:

  • Literature review and critical analysis of existing studies.
  • Consolidation of experimental and clinical data on statin effects.
  • Meta-analysis data interpretation regarding pleiotropic benefits.

Main Results:

  • Pleiotropic effects of statins, including anti-inflammatory and anti-thrombotic actions, are proposed.
  • The independent benefit of these non-lipid-lowering effects is debated, with meta-analyses challenging their absolute contribution.
  • Some evidence suggests similar effects may be observed with non-statin lipid-modifying agents.

Conclusions:

  • The precise contribution of statin's pleiotropic effects to cardiovascular outcomes remains an area of active investigation.
  • Distinguishing between lipid-lowering effects and intrinsic pleiotropic actions is crucial.
  • Further research is needed to clarify the mechanisms and clinical significance of these non-lipid-lowering properties.